Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Novartis site directory
Our Products
US Products By Brand
Patient Assistance
Product Portfolio
Our Process
Therapeutic Areas
Product Related Issues
About Us
Novartis US at a Glance
Who We Are
Diversity and Inclusion
Our Leadership
Supplier Diversity
Research
Contact Us
Corporate Responsibility
Novartis in Society US Reports
Corporate Citizenship
Business Conduct
Corporate Integrity Agreement
Payments to HCPs & HCOs
Post-Marketing Commitments
Enhanced Verification Request
News
News Archive
Statements
Stories
US Media Contacts
Novartis US COVID-19 Initiatives
Careers
Careers Search
Working at Novartis
Employee Benefits
Awards & Recognition
NIBR Careers Frequently Asked Questions
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Stories
Filter By
2021
January
Media Release
/
Jan 15, 2021
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)
Read More
2020
December
Media Release
/
Dec 15, 2020
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
Read More
Media Release
/
Dec 09, 2020
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
Read More
Media Release
/
Dec 08, 2020
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
Read More
Media Release
/
Dec 07, 2020
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
Read More
Media Release
/
Dec 01, 2020
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Read More
April
Media Release
/
Apr 30, 2020
Novartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
Read More
November
Media Release
/
Nov 19, 2020
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Read More
Media Release
/
Nov 13, 2020
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Share
Email
Jump to Comments
Print
Save
Related Links
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
You are here
Home
›
News
